Atea Pharmaceuticals, Inc. (AVIR) Investor Relations Documents

Atea Pharmaceuticals, Inc. (AVIR) investor relations documents from the company's IR site: 10 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site
PublishedTypeDocument
Press releaseAtea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipel
Press releaseAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Press releaseAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Press releaseAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2020-10-22Press releaseRead More
2020-09-14Press releaseAtea Pharmaceuticals Appoints Polly Murphy, D.V.M, Ph.D., to the Board of Directors
2020-08-24Press releaseAtea Pharmaceuticals Strengthens Management Team with Appointment of Clinical and Regulatory Leadership
2020-08-10Press releaseAtea Pharmaceuticals Appoints Janet Hammond, M.D., Ph.D., as Chief Development Officer
Press releaseShareholder Resources

AVIR overview · AVIR earnings · AVIR financials · AVIR KPIs · AVIR ownership · AVIR peers · AVIR filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.